Clinical Trials
1,294 trialsNCT03611595 2026-05-27
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
University of California, San Diego
Phase 1 Completed
NCT04958239 2026-05-27
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07438782 2026-05-27
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Recruiting
NCT05195710 2026-05-26
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT01445509 2026-05-22
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03366116 2026-05-22
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06431594 2026-05-22
BEHOLD-1
GlaxoSmithKline
Phase 1 Recruiting
NCT06551142 2026-05-22
PanTumor-101
GlaxoSmithKline
Phase 1 Recruiting
NCT06803680 2026-05-22
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07403721 2026-05-22
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
Phase 1 Recruiting
NCT07600749 2026-05-22
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
Merck Sharp & Dohme LLC
Phase 1 Not yet recruiting
NCT02321501 2026-05-20
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04585958 2026-05-20
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT00750841 2026-05-19
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT03030378 2026-05-19
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04130542 2026-05-19
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Completed
NCT04635995 2026-05-19
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Completed
NCT05372614 2026-05-18
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05678010 2026-05-18
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06626230 2026-05-18
Safety of Anal Curcumin
Emory University
Phase 1 Recruiting
NCT06952010 2026-05-14
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Recruiting
NCT07247110 2026-05-14
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07525141 2026-05-14
A Study of JNJ-1761981 in Participants With Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Recruiting
NCT05687110 2026-05-13
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05687136 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05691517 2026-05-13
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06223542 2026-05-13
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06606990 2026-05-13
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07583654 2026-05-13
Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors
West China Hospital
Phase 1 Not yet recruiting
NCT06150157 2026-05-12
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05076396 2026-05-11
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT07560943 2026-05-11
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
West China Hospital
Phase 1 Recruiting
NCT07562815 2026-05-11
Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors
West China Hospital
Phase 1 Not yet recruiting
NCT07563972 2026-05-11
Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors
West China Hospital
Phase 1 Recruiting
NCT02354547 2026-05-08
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT04401020 2026-05-08
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Sanofi
Phase 1 Active not recruiting
NCT04606381 2026-05-08
PALOMA
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04627246 2026-05-08
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer
Centre Hospitalier Universitaire Vaudois
Phase 1 Active not recruiting
NCT06178614 2026-05-08
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06311578 2026-05-08
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Recruiting
NCT04170153 2026-05-07
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono
Phase 1 Active not recruiting
NCT06046066 2026-05-07
A Phase 1 Study of NM6603 in Advanced Solid Tumors
NucMito Pharmaceuticals Co. Ltd.
Phase 1 Terminated
NCT06555744 2026-05-07
A Study of ZW191 in Participants With Solid Tumors
Zymeworks BC Inc.
Phase 1 Active not recruiting
NCT07567222 2026-05-06
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors
West China Hospital
Phase 1 Recruiting
NCT05365581 2026-05-05
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT07197671 2026-05-05
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
University of Wisconsin, Madison
Phase 1 Recruiting
NCT07563829 2026-05-04
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
NextPoint Therapeutics, Inc.
Phase 1 Not yet recruiting
NCT05378425 2026-04-30
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics Ltd
Phase 1 Active not recruiting
NCT03842228 2026-04-29
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04197713 2026-04-29
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
Phase 1 Active not recruiting